Does anybody know what the data given so far, translates to percentages? All I have heard is that there is "decrease in decline of function" and decreased exacerbations, but I get the feeling that the results haven't been as dramatic as the avg 10% seen with Kalydeco (ivacaftor) Congrats to all you nonsense mutations!